University of Veterinary Medicine Vienna - Research portal

Diagrammed Link to Homepage University of Veterinary Medicine, Vienna

Selected Publication:

Open Access Logo

Type of publication: Journal Article
Type of document: Full Paper

Year: 2016

Authors: Schinagl, A; Thiele, M; Douillard, P; Völkel, D; Kenner, L; Kazemi, Z; Freissmuth, M; Scheiflinger, F; Kerschbaumer, RJ

Title: Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer.

Source: Oncotarget. 2016; 7(45):73486-73496



Authors Vetmeduni Vienna:

Kenner Lukas

Vetmed Research Units
Institute of Pathology, Pathology of Laboratory Animals


Abstract:
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine, which was shown to be upregulated in cancers and to exhibit tumor promoting properties. Unlike other cytokines, MIF is ubiquitously present in the circulation and tissue of healthy subjects. We recently described a previously unrecognized, disease-related isoform of MIF, designated oxMIF, which is present in the circulation of patients with different inflammatory diseases. In this article, we report that oxMIF is also linked to different solid tumors as it is specifically expressed in tumor tissue from patients with colorectal, pancreatic, ovarian and lung cancer. Furthermore, oxMIF can be specifically targeted by a subset of phage display-derived fully human, monoclonal anti-MIF antibodies (mAbs) that were shown to neutralize pro-tumorigenic activities of MIF in vivo. We further demonstrate that anti-oxMIF mAbs sensitize human cancer cell lines (LNCaP, PC3, A2780 and A2780ADR) to the action of cytotoxic drugs (mitoxantrone, cisplatin and doxorubicin) in vitro and in an A2780 xenograft mouse model of ovarian cancer. We conclude that oxMIF is the disease related isoform of MIF in solid tumors and a potential new diagnostic marker and drug target in cancer.

Keywords Pubmed: Antibodies, Monoclonalpharmacology
Antineoplastic Agentspharmacology
Biomarkers, Tumor
Case-Control Studies
Cell Line, Tumor
Drug Synergism
Humans
Macrophage Migration-Inhibitory Factorsantagonists & inhibitorsbloodmetabolism
Molecular Targeted Therapy
Neoplasmsblooddrug therapymetabolismpathology
Oxidation-Reduction

© University of Veterinary Medicine ViennaHelp and DownloadsAccessibility statement